APLS – Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.APLS
$25.21Name : Apellis Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,183,768,576.00
EPSttm : -1.83
Apellis Pharmaceuticals, Inc.
$25.21
3.49%$0.85Float Short %
20.85
Margin Of Safety %
-29
Put/Call OI Ratio
0.19
EPS Next Q Diff
EPS Last/This Y
1.11
EPS This/Next Y
-0.62
Price
25.2
Target Price
37.44
Analyst Recom
2.05
Performance Q
31.23
Relative Volume
0.97
Beta
0.7
Ticker: APLS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | APLS | 26.91 | 0.26 | 0.08 | 62762 |
| 2025-09-09 | APLS | 26.84 | 0.26 | 0.79 | 63206 |
| 2025-09-10 | APLS | 26.04 | 0.25 | 0.85 | 63348 |
| 2025-09-11 | APLS | 25.41 | 0.25 | 0.28 | 63612 |
| 2025-09-12 | APLS | 24.85 | 0.25 | 2.15 | 64866 |
| 2025-09-15 | APLS | 23.63 | 0.25 | 0.10 | 64958 |
| 2025-09-16 | APLS | 23.82 | 0.25 | 0.24 | 65938 |
| 2025-09-17 | APLS | 23.13 | 0.24372105282976 | 1.0751879699248 | 66059 |
| 2025-09-18 | APLS | 23.38 | 0.25 | 0.12 | 66913 |
| 2025-09-19 | APLS | 23 | 0.25 | 0.03 | 67312 |
| 2025-09-22 | APLS | 23.5 | 0.22 | 0.49 | 61771 |
| 2025-09-23 | APLS | 23.19 | 0.19 | 0.01 | 60962 |
| 2025-09-24 | APLS | 22.84 | 0.19 | 0.97 | 61502 |
| 2025-09-25 | APLS | 22.22 | 0.19 | 0.31 | 61613 |
| 2025-09-26 | APLS | 22.37 | 0.19 | 0.03 | 61635 |
| 2025-09-29 | APLS | 22.57 | 0.19 | 0.30 | 63554 |
| 2025-09-30 | APLS | 22.63 | 0.19 | 0.19 | 62904 |
| 2025-10-01 | APLS | 23.11 | 0.19 | 0.44 | 62927 |
| 2025-10-02 | APLS | 23.13 | 0.19 | 0.12 | 62945 |
| 2025-10-03 | APLS | 23.8 | 0.19 | 0.04 | 62961 |
| 2025-10-06 | APLS | 24.34 | 0.19 | 0.07 | 63192 |
| 2025-10-07 | APLS | 25.18 | 0.19 | 0.04 | 63239 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | APLS | 26.91 | 298.5 | 51.0 | -0.40 |
| 2025-09-09 | APLS | 26.84 | 298.5 | 45.7 | -0.40 |
| 2025-09-10 | APLS | 26.05 | 298.5 | 49.2 | -0.40 |
| 2025-09-11 | APLS | 25.40 | 298.5 | 48.5 | -0.40 |
| 2025-09-12 | APLS | 24.84 | 298.5 | 48.2 | -0.40 |
| 2025-09-15 | APLS | 24.44 | 298.5 | 47.5 | -0.40 |
| 2025-09-16 | APLS | 23.82 | 298.5 | 48.4 | -0.40 |
| 2025-09-17 | APLS | 23.11 | 298.5 | 49.2 | -0.40 |
| 2025-09-18 | APLS | 23.38 | 298.5 | 43.9 | -0.40 |
| 2025-09-19 | APLS | 22.99 | 298.5 | 47.6 | -0.40 |
| 2025-09-22 | APLS | 23.49 | 298.5 | 42.6 | -0.40 |
| 2025-09-23 | APLS | 23.19 | 298.5 | 47.0 | -0.40 |
| 2025-09-24 | APLS | 22.75 | 298.5 | 47.8 | -0.40 |
| 2025-09-25 | APLS | 22.22 | 298.5 | 48.4 | -0.40 |
| 2025-09-26 | APLS | 22.37 | 298.5 | 44.4 | -0.40 |
| 2025-09-29 | APLS | 22.66 | 298.5 | 43.6 | -0.40 |
| 2025-09-30 | APLS | 22.63 | 298.5 | 45.4 | -0.40 |
| 2025-10-01 | APLS | 23.10 | 297.5 | 42.6 | -0.42 |
| 2025-10-02 | APLS | 23.11 | 297.5 | 45.2 | -0.42 |
| 2025-10-03 | APLS | 23.81 | 297.5 | 41.4 | -0.42 |
| 2025-10-06 | APLS | 24.34 | 297.5 | 38.4 | -0.42 |
| 2025-10-07 | APLS | 25.20 | 277.2 | 40.8 | -0.49 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | APLS | -1.80 | 4.80 | 19.44 |
| 2025-09-09 | APLS | -1.78 | 4.80 | 19.44 |
| 2025-09-10 | APLS | -1.97 | 4.80 | 19.44 |
| 2025-09-11 | APLS | -1.97 | 4.80 | 19.70 |
| 2025-09-12 | APLS | -2.06 | 4.80 | 19.70 |
| 2025-09-15 | APLS | -2.06 | 4.80 | 19.69 |
| 2025-09-16 | APLS | -2.06 | 4.80 | 19.69 |
| 2025-09-17 | APLS | -2.06 | 4.80 | 19.69 |
| 2025-09-18 | APLS | -2.08 | 4.80 | 19.69 |
| 2025-09-19 | APLS | -2.08 | 4.80 | 19.69 |
| 2025-09-22 | APLS | -2.22 | 4.80 | 19.69 |
| 2025-09-23 | APLS | -2.22 | 4.80 | 19.69 |
| 2025-09-24 | APLS | -2.22 | 4.80 | 19.69 |
| 2025-09-25 | APLS | -2.22 | 4.80 | 20.86 |
| 2025-09-26 | APLS | -2.22 | 4.80 | 20.85 |
| 2025-09-29 | APLS | -2.22 | 4.67 | 20.85 |
| 2025-09-30 | APLS | -2.22 | 4.67 | 20.85 |
| 2025-10-01 | APLS | -2.22 | 4.67 | 20.85 |
| 2025-10-02 | APLS | -2.22 | 4.67 | 20.85 |
| 2025-10-03 | APLS | -2.36 | 4.67 | 20.85 |
| 2025-10-06 | APLS | -2.36 | 1.55 | 20.85 |
| 2025-10-07 | APLS | -2.36 | 1.55 | 20.85 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.33
Avg. EPS Est. Current Quarter
0.91
Avg. EPS Est. Next Quarter
-0.33
Insider Transactions
-2.36
Institutional Transactions
1.55
Beta
0.7
Average Sales Estimate Current Quarter
371
Average Sales Estimate Next Quarter
211
Fair Value
17.99
Quality Score
36
Growth Score
35
Sentiment Score
78
Actual DrawDown %
73.4
Max Drawdown 5-Year %
-82.5
Target Price
37.44
P/E
Forward P/E
PEG
P/S
4.22
P/B
20.35
P/Free Cash Flow
721.94
EPS
-1.82
Average EPS Est. Cur. Y
-0.49
EPS Next Y. (Est.)
-1.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-30.24
Relative Volume
0.97
Return on Equity vs Sector %
-171.2
Return on Equity vs Industry %
-157.5
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.09
EBIT Estimation
40.8
Apellis Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 705
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today
news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance
stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market
stock prices APLS premarket after hours
ticker APLS fair value insiders trading